MILAN, Nov 26 (Reuters) - The main shareholder of

Italy's Recordati is in contact with other Italian

drugmakers over a possible sale, the chief executive of rival

Dompe Farmaceutica told Reuters on Tuesday.

Speculation about the future of Recordati increased over the

summer after majority shareholder CVC Capital Partners hired

investment banks JP Morgan and Goldman Sachs ( GS ) to

explore options for the drugmaker.

"We know there has been contact with other Italian

pharmaceuticals groups," Dompe Farmaceutica CEO Sergio Dompe

said, adding that his company was not interested in a deal.

"Recordati is a listed company that is doing very well and

the main shareholder is doing a very good job. (But) if there

are opportunities, the fund will look at them," Dompe added.

Private equity firm CVC, which owns 51.8% of Recordati,

declined to comment and a Recordati representative was not

immediately available for comment.